(P007) Pooled Analysis of Locoregional Relapse After Minimally Invasive Surgery Alone for Intermediate- or High-Risk HPV+ Oropharyngeal Squamous Cell Carcinoma

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In the HPV+ population, ECE remains a significant risk factor for LRR without adjuvant therapy after MIS. Patients with intermediate-risk disease after MIS have moderate rates of LRR.

Ryan K. Funk, MD, David G. Stoddard, MD, Kanograt Tangsriwong, MD, Michael G. Keeney, MD, Qihui Zhai, MD, Eneida F. Vencio, DDS, Alexander Lin, MD, Joaquin J. Garcia, MD, Eric J. Moore, MD, Robert L. Foote, MD, Katharine A. Price, MD, Daniel J. Ma, MD; Department of Radiation Oncology, Department of Otolaryngology, Department of Laboratory Medicine and Pathology, Division of Medical Oncology, Mayo Clinic; Department of Radiation Oncology, University of Pennsylvania; Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL; Department of Oral Pathology, School of Dentistry, Federal University Goiás

PURPOSE/OBJECTIVES: Traditional risk factors predicting locoregional relapse (LRR) following surgery for head and neck squamous cell carcinomas were identified in the pre–human papillomavirus (HPV) era. Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) present at younger age and have an approximately 50% reduction in death when compared with their HPV− counterparts. Minimally invasive surgery (MIS) (eg, transoral robotic surgery [TORS] and transoral laser microsurgery [TLM]) allows for improved intraoperative assessment of the tumor. It is unknown if traditional risk factors fully apply to the HPV+ population that undergoes MIS. We examined whether traditional indications for adjuvant radiation therapy (RT) (perineural invasion [PNI], angiolymphatic invasion [ALI], T3–4, or N2a–b) or adjuvant chemoradiation therapy (CRT) (extracapsular extension [ECE] or positive margins) also predict for LRR in patients with HPV+ OPSCC who undergo MIS alone.

MATERIALS AND METHODS: After institutional review board (IRB) approval, the medical records of patients treated with TORS (two institutions) or TLM (one institution) for OPSCC were reviewed to identify patients with HPV+ tumors who had indications for adjuvant therapy but did not receive adjuvant therapy. HPV status was confirmed by p16 immunohistochemistry. Individual data from all three institutions were pooled into a single database for analysis.

RESULTS: A total of 43 patients with HPV+ base of tongue (n = 16) or tonsil (n = 27) OPSCC with a median age of 60 years (range: 37–81 yr) who did not receive adjuvant therapy despite the presence of intermediate- or high-risk features were identified. Seventeen of 43 patients had a smoking history > 10 pack-years. Fourteen patients had ECE as an indication for CRT. Margins were close in all patients due to the nature of MIS, but the final margins were all negative. Intermediate-risk features were ALI (n = 4), PNI (n = 3), T3 (n = 6), N2a (n = 13), and N2b (n = 6). Three patients had two intermediate risk factors. Median follow-up after surgery was 30.1 months (range: 3.1–161.7 mo). Eleven of 47 (26%) patients developed LRR at a median of 5.7 months (range: 2.9–39.2 mo). Kaplan-Meier estimate of 2-year relapse-free survival was lower for patients with ECE vs patients with intermediate-risk factors only (43% vs 88%, respectively; P = .02). LRR was detected locally (n = 3, base of tongue), locally and in ipsilateral regional lymph nodes (ILNs) (n = 1), in ILNs alone (n = 4), in contralateral regional LNs (n = 2), or in bilateral neck nodes (n = 1).

CONCLUSION: In the HPV+ population, ECE remains a significant risk factor for LRR without adjuvant therapy after MIS. Patients with intermediate-risk disease after MIS have moderate rates of LRR.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content